CClinicalTrials.gg
CompletedNCT03254355Updated Jun 15, 2023

Efficacy of Physiotherapy for Urinary Incontinence in Women With a Puborectalis Avulsion

An interventional study of Multimodal physiotherapy in Urinary Incontinence, Postpartum and Pelvic Floor; Perineal Rupture, Obstetric, sponsored by Université de Sherbrooke. Completed at 1 site in Canada. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Childbirth is a major risk factor for pelvic floor muscle (PFM) trauma. In one third of women, stretching of the PFM will result in an avulsion injury (i.e. disconnection of the muscle from its insertion points on the pubic symphysis). Recent advances in imaging have led to the discovery of this previously unknown major injury and further research now enables its diagnosis with readily available techniques. Avulsion injury has alarming consequences because it has been associated with a higher rate of urinary incontinence in the postpartum period as well as the long-term development of other major urogynecological conditions such as pelvic organ prolapse and anal incontinence. Women with avulsion not only suffer from severe symptoms with significant related impacts on physical activities, overall well-being and quality of life, but they also present a higher rate of surgical failures. Moreover, it is still unknown whether the most recommended first-line treatment for urinary incontinence -PFM physiotherapy- is effective in women with this major trauma. Until now, only a pilot study conducted by our team supports the rationale and the efficacy of physiotherapy for improving PFM function in women with avulsion, despite their major muscle injury.

Primary objective: To evaluate the efficacy of physiotherapy for urinary incontinence in women with avulsion at 9-months after randomization compared to a waiting-list control group.

Secondary objectives:

  1. To compare physiotherapy to the control group after treatment and at 9-months after randomization in terms of: a) incontinence and prolapse (objective quantification, symptoms and related impact); b) PFM morphology and function; c) sexual function; d) self-efficacy; e) cost analysis; f) treatment satisfaction and impression of change.
  2. To investigate the impact of the severity of the avulsion (i.e. unilateral or bilateral) on the response to physiotherapy treatment on the aforementioned outcomes.
Read the detailed description

This is a multicenter randomized controlled trial using a parallel group design that involves women with a confirmed diagnosis of avulsion and suffering from urinary incontinence. Participants will be randomized into either physiotherapy or a waiting-list control group. Both groups will be evaluated at baseline, post-treatment (3 months post-randomization) and 9 months after randomization. Women in the control group will receive full-body relaxation massage which has shown no effect on continence but was selected to control for effects of attention received by the therapist. After the 9-month assessment, women assigned to the control group will receive the same physiotherapy treatment and undergo a last assessment.

02

Conditions studied

  • Urinary Incontinence
  • Postpartum
  • Pelvic Floor; Perineal Rupture, Obstetric
  • Physiotherapy

Keywords

  • avulsion injury
  • urinary incontinence
  • multimodal physiotherapy
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • 18-45 years old
  • Postpartum women (≥ 1 vaginal delivery at term (≥ 37 weeks) and ≥ 3 months postpartum
  • ≥ 3 urinary incontinence episodes per week over the last 3 months (Symptoms of incontinence must be associated predominantly or solely with stress urinary incontinence (as opposed to urge incontinence) which will be determined with a recommended and validated diagnosis questionnaire (Questionnaire for Urinary Incontinence Diagnosis))
  • Women with diagnosis avulsion injury

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or postmenopausal
  • Previous pelvic irradiation, urogynecological surgery, or PFM physiotherapy after the avulsion occurred
  • Significant prolapse (≥3 degree)
  • Incontinence due to other causes such as infection, neurological diseases, voiding difficulties
  • Any other acute or chronic medical problems likely to interfere with treatment or evaluation such as cancer, chronic constipation (Rome III criteria), obesity (body mass index >35), pacemaker, bladder stimulator
  • Medication or ongoing treatment likely to interfere with incontinence
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Multimodal physiotherapy

    12 weeks of weekly multimodal physiotherapy treatments

    Procedure: Multimodal physiotherapy

  • No intervention
    Waiting-list control group

    12 weeks of weekly full-body relaxation massage

Interventions

  • ProcedureMultimodal physiotherapy

    12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback

05

What researchers measure

Primary outcomes

  1. Percent reduction in the number of urinary incontinence episodes

    The 7-day bladder diary was selected as the primary outcome to measure urinary leakage reduction

    Time frame: baseline, post-treatment (3 months post-randomization) and 9 months after randomization

Secondary outcomes

  1. Change in symptoms and impact of incontinence and other urogynecological conditions

    Evaluated with ICI Modular Questionnaires (ICIQ), Pelvic Floor Distress Inventory (PFDI), Pelvic Floor Impact Questionnaire (PFIQ-SF) and Pelvic Organ Prolapse Symptom score (POP-SS)

    Time frame: baseline, post-treatment (3 months post-randomization) and 9 months after randomization

  2. Change in pelvic floor muscle morphometry and function

    Evaluated with transperineal ultrasound and dynamometry

    Time frame: baseline, post-treatment (3 months post-randomization) and 9 months after randomization

  3. Change in severity of prolapse

    Evaluated with POP-Q assessment

    Time frame: baseline, post-treatment (3 months post-randomization) and 9 months after randomization

  4. Change in sexual function

    Evaluated with Female Sexual Function Index (FSFI) and Pelvic Organ Prolapse/Incontinence Sexual Questionnaire (PISQ-SF)

    Time frame: baseline, post-treatment (3 months post-randomization) and 9 months after randomization

  5. Change in self-efficacy

    Evaluated with Broom Pelvic Muscle Self-Efficacy Scale

    Time frame: baseline, post-treatment (3 months post-randomization) and 9 months after randomization

  6. Cost analysis

    Evaluated with Dowell-Bryant Incontinence Cost Index (DBICI)

    Time frame: baseline and 9 months after randomization

  7. Treatment satisfaction and impression of change

    Evaluated with Patient Satisfaction Questionnaire (PSQ) and Patient's Global Impression of Change (PGIC)

    Time frame: baseline, post-treatment (3 months post-randomization) and 9 months after randomization

06

Study locations

1 site
  • Centre Hospitalier Universitaire de Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
07

Registry details

Key details

Study ID
NCT03254355
Lead sponsor
Université de Sherbrooke
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Mélanie Morin (Researcher and Associate Professor, Université de Sherbrooke) — Principal investigator
First posted
Aug 18, 2017
Start date
Aug 28, 2017
Primary completion
May 10, 2023
Completion
May 10, 2023
Last update
Jun 15, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion